We are live on ! Find out more
HAE icon

Haemonetics

298 hedge funds and large institutions have $4.37B invested in Haemonetics in 2024 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 104 increasing their positions, 115 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

190% more call options, than puts

Call options by funds: $14.6M | Put options by funds: $5.04M

1% more funds holding

Funds holding: 295298 (+3)

8% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 40

0.26% more ownership

Funds ownership: 100.53%100.79% (+0.26%)

0% more capital invested

Capital invested by funds: $4.36B → $4.37B (+$6.27M)

10% less repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 115

Holders
298
Holders Change
+3
Holders Change %
+1.02%
% of All Funds
4.29%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
43
Increased
104
Reduced
115
Closed
40
Calls
$14.6M
Puts
$5.04M
Net Calls
+$9.59M
Net Calls Change
-$1.66M

HAE Hedge Fund Activity: Q1 2024 in Review

298 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2024, worth a combined $4.37B — up 0.14% from $4.36B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new HAE positions and 40 closed out — a net gain of 3 holders — while 104 added to existing stakes and 115 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $78.7M. The largest seller was Fidelity Investments, cutting an estimated $109M.

  • 298 institutional investors held Haemonetics (HAE) as of Q1 2024, up from 295 in Q4 2023.
  • Funds reported $4.37B of Haemonetics stock for Q1 2024, up 0.14% quarter-over-quarter.
  • 43 funds opened new Haemonetics positions in Q1 2024 and 40 closed out, a net change of +3 holders.
  • The largest Haemonetics buyer in Q1 2024 was Wellington Management Group, an estimated $78.7M added.
  • The largest Haemonetics seller in Q1 2024 was Fidelity Investments, an estimated $109M sold.

Based on aggregated 13F filings for Q1 2024.